Assetcentricity

With some notable company building projects under its belt with the likes of platform plays Addex Pharmaceuticals Ltd., Genmab A/S and Molecular Partners AG, Index Ventures now has proof of principle for the other side of its two-headed investment strategy.

Last month, one of its "asset-centric" investments, PanGenetics B.V., sold a Phase I antibody against nerve growth factor to Abbott Laboratories for $170 million up front and the potential of another $20 million in milestones (see BioCentury, Nov. 16). ...